Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 28 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Ind-Swift Laboratories Ltd

About the Company - Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 988.09 Cr. and Equity Capital is Rs. 59.81 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh Chandigarh 160101investor@indswiftlabs.com
http://www.indswiftlabs.com
Management
NamePosition Held
Mr. Navrattan MunjalChairman & Managing Director
Mr. Himanshu JainJoint Managing Director
Mr. Rishav MehtaExecutive Director
Mr. Sahil MunjalExecutive Director
Dr. Ashwani Kumar VigIndependent Director
Mr. Rajinder Kumar GuptaIndependent Director
Mr. S P SharmaIndependent Director
Ms. Neerja ChathleyIndependent Woman Director

Ind-Swift Laboratories Ltd. Share Price Update

Share PriceValue
Today₹98.60
Previous Day₹102.70

Basic Stock Data of Ind-Swift Laboratories Ltd

Market Cap 663 Cr.
Current Price 112
High / Low123/54.0
Stock P/E23.1
Book Value 115
Dividend Yield0.00 %
ROCE13.3 %
ROE9.59 %
Face Value 10.0

Data Source: screener.in

Ind-Swift Laboratories Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales228226227250236247307280310313304310290
Expenses179178185199180194270227251259241250224
Operating Profit49484251565237535954646066
OPM %22%21%18%21%24%21%12%19%19%17%21%19%23%
Other Income59367821788-1667
Interest25262424242423242422222021
Depreciation2020281414218216161591413
Profit before tax1012-8192516-47202624163239
Tax %0%0%-264%1%3%-1%-30%1%2%-13%255%45%18%
Net Profit1012-29192416-61202528-251732
EPS in Rs1.681.95-4.943.184.142.71-10.403.364.294.65-4.252.925.36

Ind-Swift Laboratories Ltd Quarterly Chart

Ind-Swift Laboratories Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Sales1,4091,1349656606537167657577808911,0391,207
Expenses1,2311,063906571546610631630635709837978
Operating Profit178725989107106134126144183202229
OPM %13%6%6%13%16%15%18%17%19%21%19%19%
Other Income334-19-31115161203323377
Interest851401171171068828921071009692
Depreciation40546684858887104908713157
Profit before tax87-119-142-143-83-553650-20181387
Tax %-3%1%14%17%29%29%39%42%-7%117%117%45%
Net Profit89-118-122-119-59-392229-21-3-248
EPS in Rs23.50-30.02-29.79-29.14-14.33-8.754.856.09-3.59-0.53-0.368.06
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Ind-Swift Laboratories Ltd Profit & Loss Yearly Chart

Ind-Swift Laboratories Ltd Growth

Compounded Sales Growth
10 Years:1%
5 Years:10%
3 Years:16%
TTM:-1%
Compounded Profit Growth
10 Years:10%
5 Years:22%
3 Years:70%
TTM:154%
Stock Price CAGR
10 Years:13%
5 Years:21%
3 Years:14%
1 Year:68%
Return on Equity
10 Years:-3%
5 Years:0%
3 Years:3%
Last Year:10%

Ind-Swift Laboratories Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital38394142424546486060606060
Reserves784814684553476486507540581544541622671
Borrowings1,0131,2401,3551,4131,4571,2421,0831,1481,0311,005953862802
Other Liabilities383280258236240364387188198210247280267
Total Liabilities2,2182,3742,3392,2442,2152,1382,0231,9241,8701,8181,8011,8241,799
Fixed Assets9101,1711,1741,1171,0991,042934914843753630587570
CWIP294161781137870692011191088
Investments19171718181818191736293030
Other Assets9951,0251,0709971,0201,0071,0029729981,0111,1311,1991,191
Total Assets2,2182,3742,3392,2442,2152,1382,0231,9241,8701,8181,8011,8241,799

Ind-Swift Laboratories Ltd Reserves and Borrowings Chart

Ind-Swift Laboratories Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 73-47098799673-64125135150195
Cash from Investing Activity -205-480-35-29-31-17-12-9-105-13
Cash from Financing Activity 125660-64-48-69-62100-133-124-141-186
Net Cash Flow-7-290-13-4-623-17114-4

Ind-Swift Laboratories Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days79133168215208182194169186177160153
Inventory Days161180182312368305291284315301288242
Days Payable838110312013791118114124111118113
Cash Conversion Cycle157232247407439396367339377367330282
Working Capital Days16324627737925511099305313303290267
ROCE %11%2%0%1%2%2%4%4%5%7%7%13%

Ind-Swift Laboratories Ltd Financial Efficiency Indicators Chart

Ind-Swift Laboratories Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters42.00%42.00%42.00%42.00%42.00%42.00%42.00%42.01%42.01%42.01%42.01%42.01%
FIIs0.04%0.17%0.05%0.01%0.22%0.06%0.00%0.00%0.04%0.00%0.08%0.17%
DIIs19.50%19.49%19.50%19.49%19.50%19.49%19.49%19.49%19.49%19.49%19.49%19.49%
Public38.47%38.34%38.46%38.50%38.29%38.44%38.50%38.51%38.48%38.52%38.44%38.34%
No. of Shareholders14,82915,85921,46625,22524,52825,34224,91024,22624,45623,39722,96225,405

Ind-Swift Laboratories Ltd Shareholding Pattern Chart

No. of Ind-Swift Laboratories Ltd Shareholders

This stock is not held by any mutual fund

Ind-Swift Laboratories Ltd ROCE Trend

Ind-Swift Laboratories Ltd EPS Trend

Ind-Swift Laboratories Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)8.10-0.36-0.53-4.286.19
Diluted EPS (Rs.)8.10-0.36-0.53-4.285.30
Cash EPS (Rs.)17.5921.5514.0711.5227.54
Book Value[Excl.RevalReserv]/Share (Rs.)83.3667.6165.6669.4872.07
Book Value[Incl.RevalReserv]/Share (Rs.)114.02100.47100.90107.12121.73
Revenue From Operations / Share (Rs.)201.87173.68149.04130.36156.68
PBDIT / Share (Rs.)43.9239.9834.3629.7333.75
PBIT / Share (Rs.)34.3318.0719.7714.6712.21
PBT / Share (Rs.)14.472.103.01-3.3110.29
Net Profit / Share (Rs.)8.00-0.35-0.52-3.545.99
NP After MI And SOA / Share (Rs.)7.96-0.35-0.52-3.545.99
PBDIT Margin (%)21.7523.0123.0522.8021.54
PBIT Margin (%)17.0010.4013.2611.257.79
PBT Margin (%)7.161.202.02-2.536.56
Net Profit Margin (%)3.96-0.20-0.35-2.713.82
NP After MI And SOA Margin (%)3.94-0.20-0.35-2.713.82
Return on Networth / Equity (%)9.54-0.53-0.80-5.098.31
Return on Capital Employeed (%)14.137.367.865.673.75
Return On Assets (%)2.60-0.11-0.17-1.131.50
Long Term Debt / Equity (X)1.512.102.252.142.77
Total Debt / Equity (X)1.732.352.562.483.30
Asset Turnover Ratio (%)0.660.540.460.390.36
Current Ratio (X)3.143.223.002.672.35
Quick Ratio (X)1.961.941.811.611.46
Inventory Turnover Ratio (X)1.521.331.231.191.24
Interest Coverage Ratio (X)2.852.502.051.651.77
Interest Coverage Ratio (Post Tax) (X)1.810.970.960.800.41
Enterprise Value (Cr.)1173.711328.011424.061150.031307.77
EV / Net Operating Revenue (X)0.971.281.601.481.73
EV / EBITDA (X)4.475.556.936.478.02
MarketCap / Net Operating Revenue (X)0.270.380.480.160.25
Price / BV (X)0.660.981.100.310.54
Price / Net Operating Revenue (X)0.270.380.480.160.25
EarningsYield0.14-0.01-0.01-0.160.15

Ind-Swift Laboratories Ltd Profitability Ratios (%)

Ind-Swift Laboratories Ltd Liquidity Ratios

Ind-Swift Laboratories Ltd Liquidity Ratios (%)

Ind-Swift Laboratories Ltd Interest Coverage Ratios (%)

Ind-Swift Laboratories Ltd Valuation Ratios

Fair Value of Ind-Swift Laboratories Ltd Stock

Fair Value: ₹259.85

The stock is undervalued by 132.01% compared to the current price ₹112

*Investments are subject to market risks

Strength and Weakness of Ind-Swift Laboratories Ltd Stock

StrengthWeakness
    1. The stock is trading at a high valuation with an average P/B ratio of 19.81 and average Dividend Yield of 11.94%.
    2. The stock has a low average ROCE of 4.83%, which may not be favorable.
    3. The stock has a high average Working Capital Days of 250.58, which may not be favorable.
    4. The stock has a high average Cash Conversion Cycle of 328.33, which may not be favorable.
    5. The company has higher borrowings (1,123.38) compared to reserves (600.23), which may suggest financial risk.
    6. The company has not shown consistent growth in sales (515.92) and profit (-22.58).

    About the Author

    Author Avatar
    Getaka

    Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ind-Swift Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE